ARMO BioSciences Overview
- Year Founded
-
2012
- Status
-
Acquired/Merged
- Employees
-
21
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.6B
ARMO BioSciences General Information
Description
Operator of an immuno-oncology company that is developing a pipeline of products that activate the immune system of cancer patients to recognize and eradicate tumors. The company's lead product candidate, AM0010 (pegilodecakin), stimulates the survival, expansion and killing (cytotoxic) potential of a particular type of white blood cell in the immune system called CD8+ T cells, which recognize and kill cancer cells and an increased presence of intra-tumoral. In addition, the company is developing a robust immuno-oncology pipeline that includes validated product candidates such as an anti-PD-1 monoclonal antibody, aimed at treating a variety of cancers in combination with standard of care treatments and emerging immunotherapies.
Contact Information
Website
www.armobio.comCorporate Office
- 575 Chesapeake Drive
- Redwood City, CA 94063
- United States
Corporate Office
- 575 Chesapeake Drive
- Redwood City, CA 94063
- United States
ARMO BioSciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 22-Jun-2018 | $1.6B | Completed | Generating Revenue | ||
| 5. IPO | 26-Jan-2018 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series C1) | 29-Aug-2017 | Completed | Clinical Trials - Phase 3 | |||
| 3. Later Stage VC (Series C) | 10-Feb-2016 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series B) | 28-May-2014 | $30M | $50M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 20-Dec-2012 | $20M | $20M | Completed | Startup |
ARMO BioSciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C1 | ||||||||
| Series C | ||||||||
| Series B1 | ||||||||
| Series B | ||||||||
| Series A1 | 3,170,176 | $0.000100 | $0.02 | $0.25 | $0.25 | 1x | $0.25 | 2.7% |
| Series A | 19,503,817 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 16.6% |
ARMO BioSciences Comparisons
Industry
Financing
Details
ARMO BioSciences Competitors (84)
One of ARMO BioSciences’s 84 competitors is Marker Therapeutics, a Formerly VC-backed company based in Houston, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marker Therapeutics | Formerly VC-backed | Houston, TX | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Adicet Bio | Formerly VC-backed | Boston, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Unicyte | Venture Capital-Backed | Oberdorf, Switzerland |
ARMO BioSciences Patents
ARMO BioSciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3810189-A1 | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy | Pending | 19-Jun-2018 | ||
| US-20210347842-A1 | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy | Inactive | 19-Jun-2018 | ||
| US-20260356902-A1 | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy | Pending | 19-Jun-2018 | ||
| WO-2019245817-A1 | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy | Inactive | 19-Jun-2018 | ||
| JP-2022081545-A | Composition and method of use of interleukin-10 in combination with an immune checkpoint pathway inhibitor | Pending | 10-Nov-2017 | A61K38/2066 |
ARMO BioSciences Signals
ARMO BioSciences Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| Celgene | Corporation | Minority | ||
| Clough Capital Partners | Hedge Fund | Minority | ||
| Decheng Capital | Venture Capital | Minority | ||
| Duff Ackerman & Goodrich | PE/Buyout | Minority |
ARMO BioSciences Acquisitions (2)
ARMO BioSciences’s most recent deal was a Merger/Acquisition with ACIR BioSciences. The deal was made on 01-Oct-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ACIR BioSciences | 01-Oct-2015 | Merger/Acquisition | Drug Discovery | ||
| Renovo Group (Prevascar Operations) | 24-Jan-2013 | Merger/Acquisition | Drug Discovery |
ARMO BioSciences FAQs
-
When was ARMO BioSciences founded?
ARMO BioSciences was founded in 2012.
-
Where is ARMO BioSciences headquartered?
ARMO BioSciences is headquartered in Redwood City, CA.
-
What is the size of ARMO BioSciences?
ARMO BioSciences has 21 total employees.
-
What industry is ARMO BioSciences in?
ARMO BioSciences’s primary industry is Drug Discovery.
-
Is ARMO BioSciences a private or public company?
ARMO BioSciences is a Private company.
-
What is the current valuation of ARMO BioSciences?
The current valuation of ARMO BioSciences is .
-
What is ARMO BioSciences’s current revenue?
The current revenue for ARMO BioSciences is .
-
How much funding has ARMO BioSciences raised over time?
ARMO BioSciences has raised $295M.
-
Who are ARMO BioSciences’s investors?
Aisling Capital, Celgene, Clough Capital Partners, Decheng Capital, and Duff Ackerman & Goodrich are 5 of 19 investors who have invested in ARMO BioSciences.
-
Who are ARMO BioSciences’s competitors?
Marker Therapeutics, Iovance Biotherapeutics, Adicet Bio, Adaptimmune Therapeutics, and Unicyte are some of the 84 competitors of ARMO BioSciences.
-
When was ARMO BioSciences acquired?
ARMO BioSciences was acquired on 22-Jun-2018.
-
Who acquired ARMO BioSciences?
ARMO BioSciences was acquired by Lilly USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process